Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 11/20 | 0.57 |
| ▸ | CCNE1 | P24864 | 10/20 | 0.57 |
| ▸ | FLT3 | P36888 | 10/20 | 0.57 |
| ▸ | MAPKAPK2 | P49137 | 3/20 | 0.43 |
| ▸ | KIT | P10721 | 1/20 | 0.41 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.41 |
| ▸ | SYK | P43405 | 4/20 | 0.39 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.38 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3527132 | 0.93 | CDK2 (0.57) | CDK2CCNE1FLT3MAPKAPK2KIT | |
| SCHEMBL3529667 | 0.91 | CDK2 (0.59) | CDK2CCNE1FLT3MAPKAPK2KIT | |
| SCHEMBL12012864 | 0.89 | CDK2 (0.68) | CDK2CCNE1FLT3MAPKAPK2KIT | |
| SCHEMBL12013113 | 0.89 | CDK2 (0.68) | CDK2CCNE1FLT3MAPKAPK2KIT | |
| SCHEMBL3022882 | 0.87 | CDK2 (0.64) | CDK2CCNE1FLT3MAPKAPK2KIT | |
| SCHEMBL4575796 | 0.86 | CCNE1 (0.61) | CDK2CCNE1FLT3KIT | |
| SCHEMBL3020100 | 0.85 | CDK2 (0.57) | CDK2CCNE1FLT3MAPKAPK2KIT | |
| SCHEMBL3021676 | 0.85 | CDK2 (0.61) | CDK2CCNE1FLT3MAPKAPK2KIT | |
| SCHEMBL3021669 | 0.85 | CDK2 (0.61) | CDK2CCNE1FLT3MAPKAPK2KIT | |
| SCHEMBL3014537 | 0.84 | CDK2 (0.56) | CDK2CCNE1FLT3MAPKAPK2KIT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100204212-A1 | FUSED HETEROCYCLIC COMPOUNDS USEFUL AS KINASE MODULATORS | BRISTOL-MYERS SQUIBB COMPANY | 2010-08-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100204212-A1 | FUSED HETEROCYCLIC COMPOUNDS USEFUL AS KINASE MODULATORS | MAP2K2, MAP3K2, MAP4K2 | CDK2 40/4885CCNE1 468/4885FLT3 345/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.